Spondyloarthritis
Conditions
Keywords
interleukin-23, anti-IL-23 therapy, immune response, Spondyloarthritis
Brief summary
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
Detailed description
The aim of this project is to improve our understanding of the role of IL-23 in the pathophysiology of axial SpA and peripheral SpA. This objective is detailed in three specific aims: 1. Define the effects of IL-23 on gene expression and cytokine production in innate and adaptive T lymphocytes from patients with SpA, and correlate them with the patient's genotype; 2. Phenotypically characterize immune cell populations in peripheral blood and in synovial fluid from peripheral SpA patients and identify at the single cell level the cells expressing the IL-23 receptor and/or producing IL-17. The study population to be included are patients affected by SpA, attended to in the Rheumatology Departments of Cochin Hospital, Saint-Antoine Hospital Henri-Mondor hospitals in Paris (APHP) and Maison-Blanche Hospital in Reims. Participants will be divided into two groups: Group 1 comprises patients diagnosed with axial SpA, Group 2 SpA patients with peripheral SpA or psoriatic arthritis.
Interventions
OTHERBlood sampling
A 51 mL blood sample will be collected during the study
OTHERsynovial aspiration
If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
Sponsors
Institut Pasteur
Janssen Biotech, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
Two groups are included Group 1: 60 patients with axial SpA Group 2 : 30 patients with SpA or psoriatic arthritis and peripheral joint involvement, with a medical decision to treat peripheral joint inflammation by arthrocentesis
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age : Adults (\>18 years) * Satisfying ASAS diagnostic criteria for SpA * Patient has active disease, defined by the presence of active synovitis, tendinitis, or dactylitis or significant inflammatory pain of the spine, judged by the examining clinician to be due to SpA. * Informed consent signed * Beneficiary of health insurance, except for the AME Only for patients of Group 1 • Patient is naïve to biological therapies Only for patients of Group 2 * Patient is affected by peripheral SpA (ASAS criteria) or psoriatic arthritis, with inflammation of peripheral joints * Patient requires aspiration, as part of standard care Non inclusion criteria: * Patient is minor * Patient is pregnant or breastfeeding * Patient is immunocompromised * Patient has received biological therapy with 2 or more biologics * Patient is receiving corticosteroid treatment \> 10 mg per day * Patient is under legal protection, curators, guardianship * Patient refuses consent * Previous history of alcoholism, drug addiction, psychological problems, severe concomitant conditions that could invalidate the patient's consent or limit the patient's compliance to the treatment protocol. * Beneficiary of the AME Only for group 1 • Patient has received biological therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Profiling of open chromatin regions | 4 years | Profiling of open chromatin regions (ATAC seq) in T lymphocytes, cultured in the presence or absence of IL-23in order to define the effects of IL-23 on gene expression and cytokine production in innate and adaptive T lymphocytes from patients with SpA, and correlate them with the patient's genotype |
| Profiling of transcriptome | 4 years | Profiling of the transcriptome (RNA-seq) in T lymphocytes, cultured in the presence or absence of IL-23in order to define the effects of IL-23 on gene expression and cytokine production in innate and adaptive T lymphocytes from patients with SpA, and correlate them with the patient's genotype |
| Profiling of the genome | 4 years | Profiling of the genome (genotyping) in T lymphocytes, cultured in the presence or absence of IL-23in order to define the effects of IL-23 on gene expression and cytokine production in innate and adaptive T lymphocytes from patients with SpA, and correlate them with the patient's genotype |
| Profiling of cytokine expression | 4 years | Profiling of cytokine expression (Proximity Extension Assay technology) in T lymphocytes, cultured in the presence or absence of IL-23 in order to define the effects of IL-23 on gene expression and cytokine production in innate and adaptive T lymphocytes from patients with SpA, and correlate them with the patient's genotype |
| Single cell transcriptome analysis | 4 years | Single cell transcriptome analysis of cells from patients with peripheral SpA will be performed to characterize immune cell populations in peripheral blood and in synovial fluid and identify at the single cell level the cells expressing the IL-23 receptor and/or producing IL-17; |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure lymphocyte levels to explore the effects of anti-IL23 treatment on the immune responses of axSpA patients | 4 years | Define the effects in vitro of IL-23 blockade on immune responses in the peripheral blood of axSpA patients, using whole blood culture assays to profile stimulated protein secretion and gene expression, in the presence or absence of IL-23 inhibitors. As this therapy is not employed for the treatment of axSpA, we will characterize the in vitro effects of anti-IL-23 blockade on the immune responses of patients with axSpA, by analysing gene expression and protein secretion in whole blood cultures in the presence or absence of anti-IL-23 treatment. We will isolate MAIT, γδ TCR+, CD4+CCR6+ and CD8+CCR6+ (enriched in IL-23R+) T cell populations from peripheral blood of psoriasis patients and stimulate them through the T cell receptor (TCR), in the presence or absence of IL-23. |
Countries
France
Contacts
Primary ContactLars ROGGE, Dr
Outcome results
None listed